Lizzul Paul F. 4
4 · ANAPTYSBIO, INC · Filed Sep 24, 2024
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
Lizzul Paul F.
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-09-23$38.67/sh−1,500$58,005→ 15,398 total - Exercise/Conversion
Common Stock
2024-09-23$18.50/sh+1,500$27,750→ 16,898 total - Exercise/Conversion
Common
2024-09-23−1,500→ 85,000 totalExercise: $18.50Exp: 2030-07-29→ Common (1,500 underlying)
Footnotes (3)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024.
- [F2]The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- [F3]In addition to the remaining options to purchase 85,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.